Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry

被引：0

作者：

Hernando Cubero, J. ^{[1
]}

Lago, N. Martinez ^{[2
]}

Mitjavila, M. ^{[3
]}

Garcia-Burillo, A. ^{[4
]}

Pubul, V. ^{[5
]}

Bello, P. ^{[6
]}

Cano, J. M. ^{[7
]}

Llana, B. ^{[8
]}

Castellon, M. ^{[9
]}

Rodeno, E. ^{[10
]}

Pineiro, A. ^{[11
]}

Soldevilla, C. ^{[12
]}

Nevares, M. ^{[13
]}

Aller, J. ^{[14
]}

Anido Herranz, U. ^{[15
]}

Carnero Lopez, B. ^{[16
]}

Nogareda, Z. ^{[5
]}

Garcia Alvarez, A. ^{[17
]}

Jimenez Fonseca, P. ^{[18
]}

Capdevila Castillon, J. ^{[19
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Hosp Arquitecto Marcide, CHUF Complejo Hosp Univ Ferrol, Med Oncol, Ferrol, Spain

[3] Hosp Univ Puerta Hierro, Nucl Med, Majadahonda, Spain

[4] Vall dHebron Univ Hosp, Nucl Med, Barcelona, Spain

[5] Complexo Hosp Univ Santiago Compostela, Nucl Med, Santiago De Compostela, Spain

[6] Hosp Univ & Politecn La Fe, Nucl Med, Valencia, Spain

[7] Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain

[8] Hosp Univ Cent Asturias, Nucl Med, Oviedo, Spain

[9] Hosp Clin Univ Virgen de la Arrixaca, Nucl Med, El Palmar, Spain

[10] Hosp Univ Cruces, Nucl Med, Baracaldo, Spain

[11] Hosp Univ Virgen de las Nieves, Nucl Med, Granada, Spain

[12] Hosp Santa Creu & Sant Pau, Nucl Med, Barcelona, Spain

[13] Hosp Univ Burgos, Nucl Med, Burgos, Spain

[14] Hosp Univ Puerta De Hierro, Endocrinol, Majadahonda, Spain

[15] CHUS Complejo Hosp Univ Santiago de Compostela SE, Med Oncol, La Coruna, Spain

[16] Hosp Univ Lucus Augusti, Med Oncol, Lugo, Spain

[17] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[18] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain

[19] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1157P

引用

页码：S756 / S756

页数：1

共 50 条

[31] Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU
Bello, P.
Mitjavila Casanovas, M.
Jimenez-Fonseca, P.
Cabezas Agricola, J. M.
Hernando Cubero, J.
Garcia Canamaque, L.
Gajate, P.
Riesco, M. C.
Custodio, A.
Miguel Martinez, M. B.
Balaguer, D.
Carmona-Bayonas, A.
JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 177 - 177
[32] Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).
Lung, Mei Sim
Hofman, Michael
Kong, Grace
Thang, Sue-Ping
Michael, Michael
Hicks, Rodney J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: literature and practical aspects
Di Dia, Amalia
Ferrari, Mahila E.
Travaini, Laura Lavinia
Grappeja, Lorenza
Guglielmo, Priscilla
Barone, Antonio
Mei, Riccardo
Papi, Stefano
Ceci, Francesco
Grana, Chiara Maria
CLINICAL AND TRANSLATIONAL IMAGING, 2025, : 121 - 129
[34] Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)
Ladwa, R.
Pattison, D.
Smith, J.
Goodman, S.
Burge, M.
Rose, S.
Dowson, N.
Wyld, D.
NEUROENDOCRINOLOGY, 2018, 106 : 249 - 249
[35] Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H.
Song, H.
Ferri, V
Fisher, G.
Shaheen, S.
Shah, J.
Nguyen, J.
Moradi, F.
Davidzon, G.
Franc, B.
Iagaru, A.
Mari, Aparici C.
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 141 - 141
[36] Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
Kesavan, Murali
Turner, J. Harvey
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (06) : 189 - 198
[37] MYELOTOXICITY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS: A DECADE OF EXPERIENCE
Kesavan, M.
Turner, J. H.
HAEMATOLOGICA, 2016, 101 : 776 - 777
[38] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Kwekkeboom, Dik J.
de Herder, Wouter W.
van Eijck, Casper H. J.
Kam, Boen L.
van Essen, Martijn
Teunissen, Jaap J. M.
Krenning, Eric P.
SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
[39] Hepatotoxicity From Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NETs) Patients With Very High Liver Tumor Burden
Gococo-Benore, Denise A.
Parent, Ephraim
Sharma, Akash
Accurso, Joseph
Yang, Ming
Kendi, Ayse Tuba
Sonbol, Bassam
Halfdanarson, Thorvardur R.
Starr, Jason S.
PANCREAS, 2022, 51 (03) : E47 - E47
[40] Peptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumor Patients with Carcinoid Heart Disease
Prasad, V
Secknus, M. A.
Hoersch, D.
Kuntze, T.
Zachert, C.
Baum, R. P.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 133 - 133

← 1 2 3 4 5 →